Table 1

Baseline characteristics of participants
Control NA= 12 Intervention NB= 16 P value (A-B)
Demographics
Age (y)1 81.8 (7.1, 71–94) 85.1 (6.7, 70–98) 0.233
Gender Male:Female 5:7 7:9 0.609
Ethnicity White British 12 (100%) 16 (100%) -
Care Home Type2 N:R:D 5:7:0 3:10:3 0.171
Body Mass Index1 25.5 (4.6, 20.8-36.4) 27.7 (4.8, 19.5-35.9)
Heart failure
Heart Failure3 Confirmed:New 6:6 9:7 1.000
NYHA4 class I:II:III:IV 5:4:1:1 10:1:4:1 0.213
Ejection Fraction (mean %, SD) 43 (6.3) 33 (1.4) 0.146
Total no of co-morbidities (mean, SD)5 4.67 (2.1) 4.50 (1.5) 0.319
Renal Function
Urea Abnormal6 8 (75%) 9 (56%) 0.705
Creatinine Abnormal7 2 (17%) 5 (31%) 0.558
Prescribed drugs8
ACEi and β blocker 3 (25%) 6 (38%) 0.687
ACEi 6 (50%) 7 (44%) 1.000
β blocker 5 (42%) 9 (56%) 0.704
Angiotensin Receptor Blocker 0 (0%) 0 (0%) -
Calcium Channel Blocker 1 (8%) 4 (25%) 0.355
Diuretic 8 (67%) 9 (56%) 0.705
Statin 7 (58%) 8 (50%) 0.718
Digoxin 4 (33%) 1 (6%) 0.133
Antiplatelet 7 (58%) 10 (63%) 1.000
Spironolactone 0 (0%) 0 (0%) -
Bronchodilators 4 (33%) 2 (13%) 0.354
Warfarin 3 (25%) 1 (6%) 0.285
Non Steroidal Anti-Inflammatory Drugs 0 (0%) 1 (6%) 1.000
Total no of prescribed drugs (mean, SD) 10.3 (3.4) 9.5 (4.7) 0.287

1 Mean (standard deviation, range).

2 Nursing:Residential:Dementia.

3 Confirmed cases pre-existed in general practice HF register records.

4 New York Heart Association [34].

5 From a predefined list of co-morbidities (MI, IHD, Hypertension, AF, valvular heart disease, diabetes, COPD, osteoarthritis, cognitive impairment).

6 Outside normal limits (2.5-7.0mmol/l).

7 Outside normal limits (50-110μmol/l).

8 As recorded in GP notes.

Hancock et al.

Hancock et al. BMC Geriatrics 2012 12:70   doi:10.1186/1471-2318-12-70

Open Data